Fig. 2

In situ replenishment of Ly6C⁻macrophages compensates for CCR2 deficiency-induced macrophage sparsity in CCR2^−/−kidneys during the chronic phase after I/R injury. a Representative images (left) and quantitative analyses (right) for immunofluorescence labeled F4/80 (green) in the WT and CCR2^−/− kidneys at d3 and d20 after I/R. b Q-PCR for F4/80 mRNA level during AKI to CKD progression. c Representative images (left) and double-positive analyses (right) for immunofluorescence-labeled F4/80 (green) and Ki67(red) in the WT and CCR2^−/− kidneys at d20 after I/R. d Q-PCR for levels of macrophage growth factors CSF1, CSF2, and IL34 in CCR2^−/− and WT kidneys from AKI to CKD. e Scheme. cell-sorting approach. f The percentage (left) and number (right) of Ly6C⁻ macrophage analyses by flow cytometry from the whole kidneys in the WT and CCR2^−/− mice. g The percentage (left) and number (right) of Ly6C⁺ macrophage analyses by flow cytometry from the whole kidneys in the WT and CCR2^−/− mice. Scale bars, 100 μm. N = 4–6/group. *P < 0.05, **P < 0.01, ***P < 0.001. Values were means±SD. Mø, macrophages